Physician Assistant Program year 2025 Reported 2021–2025 Source: CMS Open Payments, 2026 publication

Ashley Guy

Physician Assistant Fairhope, AL Physician Assistant

NPI 1619924180 CMS profile 10920718

394 Fruit Tree Ln, Fairhope, AL 36532

Open in the dashboard

General payments

$2,643

112 records reported · program years 2021–2025

Research payments

$0

Paid to them · None reported · program years 2021–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Ashley Guy of Fairhope, AL is reported in the CMS Open Payments database as having received $2,643 across 112 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 84th percentile of Physician Assistant profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

5 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $21 1
2024 General $47 2
2023 General $208 11
2022 General $1,319 60
2021 General $1,048 38

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Ashley Guy
  • Physician Assistant median
  • Middle half of Physician Assistant
  • National median

In program year 2025, general payments to Ashley Guy were reported at $21. Among 68,903 Physician Assistant profiles paid that year, the median was $184 and the middle half received between $57 and $620.

Show as a table
Year Ashley Guy Physician Assistant median Middle half National median
2019 $0 $34 $17–$122 $163
2020 $0 $33 $16–$78 $114
2021 $1,048 $132 $37–$438 $132
2022 $1,319 $155 $48–$522 $149
2023 $208 $167 $52–$557 $160
2024 $47 $178 $55–$600 $164
2025 $21 $184 $57–$620 $169

Breakdown

Who paid General payments · program years 2021–2025
  1. Astellas Pharma US Inc $362 7 payments
  2. Endo Pharmaceuticals Inc. $302 10 payments
  3. Coloplast Corp $298 10 payments
  4. Antares Pharma, Inc. $283 20 payments
  5. Janssen Biotech, Inc. $182 11 payments
  6. Axonics Modulation Technologies, Inc. $181 2 payments
  7. Baxter Healthcare $180 4 payments
  8. Myovant Sciences Inc. $96 7 payments
  9. Boston Scientific Corporation $95 4 payments
  10. Pfizer Inc. $85 4 payments
  11. Other $578 33 payments

Every payment, record by record

What the payments were for General payments · program years 2021–2025
  1. Food and Beverage $2,343 109 payments
  2. Education $300 3 payments
Products named General payments · program years 2021–2025
  1. XIAFLEX $302 10 payments
  2. SpeediCath $286 9 payments
  3. NOCDURNA $203 15 payments
  4. XYOSTED $203 15 payments
  5. AVEED $187 9 payments
  6. EDEX $187 9 payments
  7. ERLEADA $182 11 payments
  8. TLANDO $150 12 payments
  9. FLOSEAL $128 2 payments
  10. Axonics r-SNM System $116 1 payment
  11. Other $1,438 76 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 11 drugs

Part D claims

280

Median for Physician Assistant: 241

Drug cost

$9,725

Median for Physician Assistant: $4,110

Branded share of claims

36.4%

Median for Physician Assistant: 19.6%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Myrbetriq Mirabegron Brand 14 $7,080
Cefdinir Generic 34 $837
Doxycycline Hyclate Generic 47 $484
Amoxicillin-Clavulanate Potass Amoxicillin/Potassium Clav Brand 36 $410
Nitrofurantoin Mono-Macro Nitrofurantoin Monohyd/M-Cryst Brand 17 $354
Azithromycin Generic 40 $173
Albuterol Sulfate Hfa Albuterol Sulfate Brand 11 $159
Ciprofloxacin Hcl Generic 14 $120
Cephalexin Generic 18 $88
Prednisone Generic 25 $21

The 10 drugs with the highest cost, of 11 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 114,276 Part D prescribers listed as Physician Assistant; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 59 billing codes

Paid by Medicare

$31,956

Of which drugs: $262

Medicare patients

255

Average age 75

Services billed

1,043

172 women, 83 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 69%
Arthritis 59%
Ischemic heart disease 29%
Depression 22%
Osteoporosis 21%
Chronic kidney disease 20%
Diabetes 19%
Atrial fibrillation 18%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Injection, ceftriaxone sodium, per 250 mg J0696 Office 15 50 $16
Injection, dexamethasone sodium phosphate, 1 mg J1100 Office 17 108 $8

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

112 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Physician Assistant in Alabama

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record